
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="../style.css">
    <title>Document</title>
</head>
<body>

<span class="table_title">False Negatives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>62</th>
      <td></td>
      <td>500 mg</td>
      <td>Another patient experienced liver injury after taking 500 mg leaf powder every 2–3 days as a laxative [117].</td>
    </tr>
    <tr>
      <th>54</th>
      <td></td>
      <td>0.2 mg/kg<br>240 or 480 mg/kg</td>
      <td>Sixty Sprague–Dawley rats were used to investigate the effects of warfarin (0.2 mg/kg), Danshen (240 or 480 mg/kg) and Gegen (240 or 480 mg/kg) both in isolation and combination.</td>
    </tr>
    <tr>
      <th>34</th>
      <td></td>
      <td>120 mg<br>240 mg</td>
      <td>The following treatments were administered for 8 days each: placebo twice daily (treatment A), EGb 761® 120 mg twice daily (treatment B), and EGb 761® 240 mg in the morning and placebo in the evening (treatment C).</td>
    </tr>
    <tr>
      <th>28</th>
      <td></td>
      <td>180 mg/dL<br>160/100 mmHg</td>
      <td>Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone–related cancers; 4) women with uncontrolled hypertension (160/100 mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1 yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk; 12) women who were administered female hormone formulations within 6 mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10 h) within 3 mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1 mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.</td>
    </tr>
    <tr>
      <th>57</th>
      <td></td>
      <td>40 mg</td>
      <td>(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.</td>
    </tr>
    <tr>
      <th>30</th>
      <td></td>
      <td>0.5–2.0 g/kg</td>
      <td>In case of ginseng interactions, it was reported that no herb–drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5–2.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].</td>
    </tr>
    <tr>
      <th>47</th>
      <td></td>
      <td>5 mg</td>
      <td>5 mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306 ng/mL), and Iscador Qu spec.</td>
    </tr>
    <tr>
      <th>56</th>
      <td></td>
      <td>500 mg</td>
      <td>The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.</td>
    </tr>
    <tr>
      <th>37</th>
      <td></td>
      <td>240-mg</td>
      <td>A maximum exposure was realized with a 240-mg EGb 761® daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761® components was reached, and 1 week is typically sufficient to achieve full induction [35].</td>
    </tr>
    <tr>
      <th>33</th>
      <td></td>
      <td><50 copies/ml</td>
      <td>No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.</td>
    </tr>
    <tr>
      <th>43</th>
      <td></td>
      <td>2 × 10</td>
      <td>Briefly, 2 × 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).</td>
    </tr>
    <tr>
      <th>65</th>
      <td></td>
      <td>between 7.5 and 15 mg<br>+28%</td>
      <td>With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.</td>
    </tr>
    <tr>
      <th>13</th>
      <td></td>
      <td>1000 mg</td>
      <td>To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg × 4 times (8 tablets) per day for treatment of the common cold [22,23].</td>
    </tr>
    <tr>
      <th>19</th>
      <td></td>
      <td>1,200 mg</td>
      <td>In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.</td>
    </tr>
    <tr>
      <th>60</th>
      <td></td>
      <td>74.27 µmol/L</td>
      <td>At that time the serum creatinine level was 74.27 µmol/L and was stable.</td>
    </tr>
    <tr>
      <th>16</th>
      <td></td>
      <td>1000 mg<br>7680 mg</td>
      <td>AAP at 1000 once a day or 1000 mg × 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.</td>
    </tr>
    <tr>
      <th>46</th>
      <td></td>
      <td>40 mg/kg</td>
      <td>on the 7th day, 2 h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.</td>
    </tr>
    <tr>
      <th>7</th>
      <td></td>
      <td>0.1%<br>0.1% (v/v)</td>
      <td>DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.</td>
    </tr>
    <tr>
      <th>36</th>
      <td></td>
      <td>120 mg</td>
      <td>Administration of EGb 761® 120 mg b.i.d.</td>
    </tr>
    <tr>
      <th>45</th>
      <td></td>
      <td>25 mg/kg)</td>
      <td>Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.</td>
    </tr>
    <tr>
      <th>53</th>
      <td></td>
      <td>6 g</td>
      <td>However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.</td>
    </tr>
    <tr>
      <th>2</th>
      <td></td>
      <td>1%<br>200 μL<br>10%</td>
      <td>Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 μL in 96-well microplates.</td>
    </tr>
    <tr>
      <th>38</th>
      <td></td>
      <td>more than 37 seconds<br>greater than seven<br>more than 70 seconds</td>
      <td>At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.</td>
    </tr>
    <tr>
      <th>31</th>
      <td></td>
      <td>1 mg/kg</td>
      <td>AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.</td>
    </tr>
    <tr>
      <th>50</th>
      <td></td>
      <td>1.7–2.5<br>1.875 mg</td>
      <td>The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7–2.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.</td>
    </tr>
    <tr>
      <th>23</th>
      <td></td>
      <td>600 mg</td>
      <td>Recommended daily doses of valerian root extracts are about 600 mg, usually taken as capsules or tablets.</td>
    </tr>
    <tr>
      <th>44</th>
      <td></td>
      <td>25 mg/kg</td>
      <td>The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.</td>
    </tr>
    <tr>
      <th>14</th>
      <td></td>
      <td>1000 mg<br>7680 mg</td>
      <td>Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg × 4 times daily + GGT 7680 mg once daily) in a week.</td>
    </tr>
    <tr>
      <th>58</th>
      <td></td>
      <td>500 μg/mL<br>100 μg/mL</td>
      <td>The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500 μg/mL) and all the herbal components (100 μg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.</td>
    </tr>
    <tr>
      <th>22</th>
      <td></td>
      <td>10 mg</td>
      <td>(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10 mg), which made this end point difficult to assess.</td>
    </tr>
    <tr>
      <th>5</th>
      <td></td>
      <td>23.9%<br>21.4%</td>
      <td>Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).</td>
    </tr>
    <tr>
      <th>0</th>
      <td></td>
      <td>1 : 40<br>1 : 80</td>
      <td>Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.</td>
    </tr>
    <tr>
      <th>32</th>
      <td></td>
      <td>498</td>
      <td>The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.</td>
    </tr>
    <tr>
      <th>18</th>
      <td></td>
      <td>600 mg</td>
      <td>In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).</td>
    </tr>
    <tr>
      <th>24</th>
      <td></td>
      <td>500 mg</td>
      <td>Daily before going to bed, participants took two tablets, with 500 mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51 mg/tablet), for 14 subsequent days.</td>
    </tr>
    <tr>
      <th>20</th>
      <td></td>
      <td>1200 mg<br>1200mg</td>
      <td>With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.</td>
    </tr>
    <tr>
      <th>64</th>
      <td></td>
      <td>5 ppm</td>
      <td>For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].</td>
    </tr>
    <tr>
      <th>25</th>
      <td></td>
      <td>38 mg/kg bw</td>
      <td>Haloperidol (38 mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].</td>
    </tr>
    <tr>
      <th>26</th>
      <td></td>
      <td>1000 mg<br>600 mg</td>
      <td>Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.</td>
    </tr>
    <tr>
      <th>11</th>
      <td></td>
      <td>3 mg/kg<br>5 mg/kg</td>
      <td>Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.</td>
    </tr>
    <tr>
      <th>48</th>
      <td></td>
      <td>4.5 mg/200 g BW</td>
      <td>daily for two weeks at morning and a single captopril dose (4.5 mg/200 g BW; p.o.)</td>
    </tr>
    <tr>
      <th>67</th>
      <td></td>
      <td>25 μg/ml</td>
      <td>The activation was highest at 25 μg/ml concentration.</td>
    </tr>
    <tr>
      <th>9</th>
      <td></td>
      <td>330 µg/ml<br>> 1000 µg/ml</td>
      <td>The strongest reversible inhibition was against CYP2C9 (IC50 330 µg/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 µg/ml).</td>
    </tr>
    <tr>
      <th>63</th>
      <td></td>
      <td>0.45%</td>
      <td>The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].</td>
    </tr>
    <tr>
      <th>41</th>
      <td></td>
      <td>68 µg/mL<br>150 µg/mL</td>
      <td>There was no significant difference between BNPP (68 µg/mL) and PNS (150 µg/mL).</td>
    </tr>
    <tr>
      <th>49</th>
      <td></td>
      <td>6</td>
      <td>(n = 6).</td>
    </tr>
    <tr>
      <th>52</th>
      <td></td>
      <td>375 ml</td>
      <td>[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.</td>
    </tr>
  </tbody>
</table>
<span class="table_title">False Positives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>4</th>
      <td>69.90%<br>65.38%</td>
      <td></td>
      <td>The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).</td>
    </tr>
    <tr>
      <th>6</th>
      <td>recombinant CYP2C8 enzyme (supersomes)<br>human liver microsomes (HLM)</td>
      <td></td>
      <td>An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism‐based inhibitors and was characterised by a high lot‐to‐lot variability.</td>
    </tr>
    <tr>
      <th>0</th>
      <td>different parts of E. purpurea plants<br>roots<br>DTAI<br>leaves</td>
      <td></td>
      <td>For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.</td>
    </tr>
  </tbody>
</table>

</body>
</html>
